LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article ; Online: Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin's lymphoma.

    Lee, Joycelyn J X / Chan, Alexandre / Tang, Tiffany

    Acta oncologica (Stockholm, Sweden)

    2016  Volume 55, Issue 4, Page(s) 519–520

    MeSH term(s) Aged, 80 and over ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antitubercular Agents/therapeutic use ; Hodgkin Disease/drug therapy ; Hodgkin Disease/microbiology ; Hodgkin Disease/pathology ; Humans ; Lymph Nodes/diagnostic imaging ; Lymph Nodes/pathology ; Male ; Molecular Targeted Therapy ; Mycobacterium tuberculosis/isolation & purification ; Mycobacterium tuberculosis/pathogenicity ; Neoplasm Recurrence, Local ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Tomography, X-Ray Computed ; Tuberculosis/chemically induced ; Tuberculosis/drug therapy
    Chemical Substances Antibodies, Monoclonal, Humanized ; Antitubercular Agents ; PDCD1 protein, human ; Programmed Cell Death 1 Receptor ; pembrolizumab (DPT0O3T46P)
    Language English
    Publishing date 2016
    Publishing country England
    Document type Case Reports ; Letter
    ZDB-ID 896449-x
    ISSN 1651-226X ; 0349-652X ; 0284-186X ; 1100-1704
    ISSN (online) 1651-226X
    ISSN 0349-652X ; 0284-186X ; 1100-1704
    DOI 10.3109/0284186X.2015.1125017
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6348: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Clinical Development of c-MET Inhibition in Hepatocellular Carcinoma.

    Lee, Joycelyn J X / Chan, Jack J / Choo, Su Pin

    Diseases (Basel, Switzerland)

    2015  Volume 3, Issue 4, Page(s) 306–324

    Abstract: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death. In patients with advanced or unresectable HCC, there are few treatment options. Conventional chemotherapy has limited benefits. Sorafenib, a multi-kinase inhibitor, improves ... ...

    Abstract Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death. In patients with advanced or unresectable HCC, there are few treatment options. Conventional chemotherapy has limited benefits. Sorafenib, a multi-kinase inhibitor, improves survival, but options for patients intolerant of or progressing on sorafenib are limited. There has been much interest in recent years in molecular therapeutic targets and drug development for HCC. One of the more promising molecular targets in HCC is the cellular-mesenchymal-epithelial transition (c-MET) factor receptor. Encouraging phase II data on two c-MET inhibitors, tivantinib and cabozantinib, has led to phase III trials. This review describes the c-MET/hepatocyte growth factor (HGF) signalling pathway and its relevance to HCC, and discusses the preclinical and clinical trial data for inhibitors of this pathway in HCC.
    Language English
    Publishing date 2015-10-28
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2720869-2
    ISSN 2079-9721
    ISSN 2079-9721
    DOI 10.3390/diseases3040306
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Clinical Development of c-MET Inhibition in Hepatocellular Carcinoma

    Joycelyn J. X. Lee / Jack J. Chan / Su Pin Choo

    Diseases, Vol 3, Iss 4, Pp 306-

    2015  Volume 324

    Abstract: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death. In patients with advanced or unresectable HCC, there are few treatment options. Conventional chemotherapy has limited benefits. Sorafenib, a multi-kinase inhibitor, improves ... ...

    Abstract Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death. In patients with advanced or unresectable HCC, there are few treatment options. Conventional chemotherapy has limited benefits. Sorafenib, a multi-kinase inhibitor, improves survival, but options for patients intolerant of or progressing on sorafenib are limited. There has been much interest in recent years in molecular therapeutic targets and drug development for HCC. One of the more promising molecular targets in HCC is the cellular-mesenchymal-epithelial transition (c-MET) factor receptor. Encouraging phase II data on two c-MET inhibitors, tivantinib and cabozantinib, has led to phase III trials. This review describes the c-MET/hepatocyte growth factor (HGF) signalling pathway and its relevance to HCC, and discusses the preclinical and clinical trial data for inhibitors of this pathway in HCC.
    Keywords hepatocellular carcinoma (HCC) ; c-MET ; hepatocyte growth factor (HGF) ; c-MET inhibitor ; tivantinib ; cabozantinib ; Medicine ; R
    Subject code 610
    Language English
    Publishing date 2015-10-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article ; Online: Immunohistochemical scoring of LAG-3 in conjunction with CD8 in the tumor microenvironment predicts response to immunotherapy in hepatocellular carcinoma.

    Cheung, Chun Chau Lawrence / Seah, Yong Hock Justin / Fang, Juntao / Orpilla, Nicole Hyacinth Calpatura / Lau, Mai Chan / Lim, Chun Jye / Lim, Xinru / Lee, Justina Nadia Li Wen / Lim, Jeffrey Chun Tatt / Lim, Sherlly / Cheng, Qing / Toh, Han Chong / Choo, Su Pin / Lee, Suat Ying / Lee, Joycelyn Jie Xin / Liu, Jin / Lim, Tony Kiat Hon / Tai, David / Yeong, Joe

    Frontiers in immunology

    2023  Volume 14, Page(s) 1150985

    Abstract: Introduction: Immune checkpoint blockade (ICB) is a systemic therapeutic option for advanced hepatocellular carcinoma (HCC). However, low patient response rates necessitate the development of robust predictive biomarkers that identify individuals who ... ...

    Abstract Introduction: Immune checkpoint blockade (ICB) is a systemic therapeutic option for advanced hepatocellular carcinoma (HCC). However, low patient response rates necessitate the development of robust predictive biomarkers that identify individuals who will benefit from ICB. A 4-gene inflammatory signature, comprising
    Methods: HCC samples from 191 Asian patients, comprising resection specimens from 124 patients (ICB-naïve) and pre-treatment specimens from 67 advanced HCC patients treated with ICB (ICB-treated), were analyzed for CD8, PD-L1, LAG-3, and STAT1 tissue expression using multiplex immunohistochemistry followed by statistical and survival analyses.
    Results: Immunohistochemical and survival analyses of ICB-naïve samples showed that high LAG-3 expression was associated with shorter median progression-free survival (mPFS) and overall survival (mOS). Analysis of ICB-treated samples revealed that high proportions of LAG-3
    Conclusion: Immunohistochemical scoring of pre-treatment levels of LAG-3 and CD8 in the tumor microenvironment may help predict ICB benefits in HCC patients. Furthermore, immunohistochemistry-based techniques offer the advantage of being readily translatable in the clinical setting.
    MeSH term(s) Humans ; Carcinoma, Hepatocellular/metabolism ; Liver Neoplasms ; Tumor Microenvironment ; CD8-Positive T-Lymphocytes ; Immunotherapy/methods
    Language English
    Publishing date 2023-06-05
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2023.1150985
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Multimodal molecular landscape of response to Y90-resin microsphere radioembolization followed by nivolumab for advanced hepatocellular carcinoma.

    Kaya, Neslihan Arife / Tai, David / Lim, Xinru / Lim, Jia Qi / Lau, Mai Chan / Goh, Denise / Phua, Cheryl Zi Jin / Wee, Felicia Yu Ting / Joseph, Craig Ryan / Lim, Jeffrey Chun Tatt / Neo, Zhen Wei / Ye, Jiangfeng / Cheung, Lawrence / Lee, Joycelyn / Loke, Kelvin S H / Gogna, Apoorva / Yao, Fei / Lee, May Yin / Shuen, Timothy Wai Ho /
    Toh, Han Chong / Hilmer, Axel / Chan, Yun Shen / Lim, Tony Kiat-Hon / Tam, Wai Leong / Choo, Su Pin / Yeong, Joe / Zhai, Weiwei

    Journal for immunotherapy of cancer

    2023  Volume 11, Issue 8

    Abstract: Background: Combination therapy with radioembolization (yttrium-90)-resin microspheres) followed by nivolumab has shown a promising response rate of 30.6% in a Phase II trial (CA209-678) for advanced hepatocellular carcinoma (HCC); however, the response ...

    Abstract Background: Combination therapy with radioembolization (yttrium-90)-resin microspheres) followed by nivolumab has shown a promising response rate of 30.6% in a Phase II trial (CA209-678) for advanced hepatocellular carcinoma (HCC); however, the response mechanisms and relevant biomarkers remain unknown.
    Methods: By collecting both pretreatment and on-treatment samples, we performed multimodal profiling of tissue and blood samples and investigated molecular changes associated with favorable responses in 33 patients from the trial.
    Results: We found that higher tumor mutation burden,
    Conclusions: This study unraveled extensive molecular changes underlying distinctive responses to the novel treatment and pinpointed new directions for harnessing combination therapy in patients with advanced HCC.
    MeSH term(s) Humans ; Carcinoma, Hepatocellular/drug therapy ; Carcinoma, Hepatocellular/genetics ; Microspheres ; Nivolumab/pharmacology ; Nivolumab/therapeutic use ; Liver Neoplasms/drug therapy ; Liver Neoplasms/genetics ; Chromosome Deletion
    Chemical Substances Nivolumab (31YO63LBSN) ; Yttrium-90 (1K8M7UR6O1)
    Language English
    Publishing date 2023-08-16
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2719863-7
    ISSN 2051-1426 ; 2051-1426
    ISSN (online) 2051-1426
    ISSN 2051-1426
    DOI 10.1136/jitc-2023-007106
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma.

    Ng, Harry Ho Man / Lee, Ren Yuan / Goh, Siting / Tay, Isabel Shu Ying / Lim, Xinru / Lee, Bernett / Chew, Valerie / Li, Huihua / Tan, Benedict / Lim, Sherlly / Lim, Jeffrey Chun Tatt / Au, Bijin / Loh, Josh Jie Hua / Saraf, Sahil / Connolly, John Edward / Loh, Tracy / Leow, Wei Qiang / Lee, Joycelyn Jie Xin / Toh, Han Chong /
    Malavasi, Fabio / Lee, Ser Yee / Chow, Pierce / Newell, Evan W / Choo, Su Pin / Tai, David / Yeong, Joe / Lim, Tony Kiat Hon

    Journal for immunotherapy of cancer

    2020  Volume 8, Issue 2

    Abstract: Introduction: Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-associated mortality globally. Immune-checkpoint blockade (ICB) is one of the systemic therapy options for HCC. However, response rates remain low, necessitating robust ... ...

    Abstract Introduction: Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-associated mortality globally. Immune-checkpoint blockade (ICB) is one of the systemic therapy options for HCC. However, response rates remain low, necessitating robust predictive biomarkers. In the present study, we examined the expression of CD38, a molecule involved in the immunosuppressive adenosinergic pathway, on immune cells present in the tumor microenvironment. We then investigated the association between CD38 and ICB treatment outcomes in advanced HCC.
    Methods: Clinically annotated samples from 49 patients with advanced HCC treated with ICB were analyzed for CD38 expression using immunohistochemistry (IHC), multiplex immunohistochemistry/immunofluorescence (mIHC/IF) and multiplex cytokine analysis.
    Results: IHC and mIHC/IF analyses revealed that higher intratumoral CD38
    Conclusions: A high proportion of CD38
    MeSH term(s) ADP-ribosyl Cyclase 1/metabolism ; Aged ; B7-H1 Antigen/immunology ; Carcinoma, Hepatocellular/immunology ; Carcinoma, Hepatocellular/pathology ; Female ; Humans ; Immunohistochemistry/methods ; Immunotherapy/methods ; Liver Neoplasms/immunology ; Liver Neoplasms/pathology ; Male ; Tumor Microenvironment/immunology
    Chemical Substances B7-H1 Antigen ; CD274 protein, human ; ADP-ribosyl Cyclase 1 (EC 3.2.2.6)
    Language English
    Publishing date 2020-09-15
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2719863-7
    ISSN 2051-1426 ; 2051-1426
    ISSN (online) 2051-1426
    ISSN 2051-1426
    DOI 10.1136/jitc-2020-000987
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top